NCT03812198 - A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2019

Primary Completion Date

June 13, 2019

Study Completion Date

June 13, 2019

Conditions

Healthy

Interventions

DRUG

LEO 32731 modified release tablet

At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.

DRUG

LEO 32731 blend, hard capsule

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

DRUG

LEO 32731 API, hard capsule

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

DRUG

LEO 32731 soft capsule

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

DRUG

LEO 32731 gastro-resistant capsule

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

DRUG

LEO 32731

At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

OTHER

Placebo

At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Trial Locations (1)

LEO Pharma Investigational Site, Leeds